EQS-Adhoc: IGEA Pharma N.V.: IGEA announces changes in its board and other corporate updates
IGEA announces changes in its board and other corporate updates
03-Jun-2021 / 23:19 CET/CEST
Release of an ad hoc announcement pursuant to Art. 18 KR
The issuer is solely responsible for the content of this announcement.
IGEA announces changes in its board and other corporate updates
Hoofddorp, the Netherlands, 3 June 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mrs. Rosanna Squitti and Mr. Giovanni Ferrario from its board of directors. Mr. Ferrario resigned for personal reasons and Mrs. Squitti left the corporate body for continuing to serve as Chief Scientific Officer of the Company. The Board furthermore elected Mrs. Giovanna Puppo as new Chairman, substituting Mr. Francesco Mario Patrocollo who will newly assume the role of vice Chairman.
IGEA Pharma N.V. / Key word(s): Annual Results31-May-2021 / 23:33 CET/CESTRelease of an ad hoc announcement pursuant to Art. 18 KRThe issuer is solely responsible for the content of this announcement.IGEA disclosed its Annual Report 2020Hoofddorp, the Netherlands, 31 May 2021. IGEA Pharma N.V. (SIX: IGPH) today anno.
EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Annual Results IGEA disclosed its Annual Report 2020 31-May-2021 / 23:33 CET/CEST Release of an ad hoc announcement pursuant to Art. 18 KR The issuer
EQS-Adhoc: IGEA Pharma N.V.: IGEA to get SIX approval to delay the 2020 annual report disclosure
IGEA to get SIX approval to delay the 2020 annual report disclosure
30-Apr-2021 / 22:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 18 KR
The issuer is solely responsible for the content of this announcement.
IGEA to get SIX approval to delay the 2020 annual report disclosure
Hoofddorp, the Netherlands, 30 April 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2020 annual report.
As anticipated on 28 April 2021, certain decisions taken by the last extraordinary general meeting, following which a relevant business combination process and changes in the corporate governance have been approved, required to have all implications of such matters on the Company s reporting obligations adequately presented, leading to a delay in disclosing the 2020 annual report. IGEA expects to discl
IGEA to get SIX approval to delay the 2020 annual report disclosure
IGEA Pharma N.V. / Key word(s): Miscellaneous
30-Apr-2021 / 22:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 18 KR
The issuer is solely responsible for the content of this announcement.
IGEA to get SIX approval to delay the 2020 annual report disclosure
Hoofddorp, the Netherlands, 30 April 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2020 annual report.
As anticipated on 28 April 2021, certain decisions taken by the last extraordinary general meeting, following which a relevant business combination process and changes in the corporate governance have been approved, required to have all implications of such matters on the Company s reporting obligations adequately presented, leading to a delay in disclosing the 2020 annual report. IGEA expects to disclose its 2020 annual report within the next coming w